Skip to main content
. 2021 Oct 10;11(10):1066. doi: 10.3390/life11101066

Figure 4.

Figure 4

Kaplan–Meier curves of overall survival (OS) rates before (a) and after (b) PSM. (a) The median OS times were 16.0 months for TACE plus sorafenib and 12.2 months for TACE alone before PSM (p = 0.023). (b) The median OS times were 17.5 months for TACE plus sorafenib and 12.8 months for TACE alone after PSM (p = 0.049).